Clinical Intelligence/Clinical Efficiency

BioIntelliSense and Medically Home Announce Strategic Collaboration


The collaboration further expands the availability of continuous biometric data and insights to physicians and nurses caring for patients in the Medically Home model with serious, complex or high-risk illness being cared for in their homes while accelerating the adoption of medical grade BioButton® wearable devices

BioIntelliSense, Inc., a continuous health monitoring and clinical intelligence company, today announced it has entered into a strategic partnership with Medically Home Group, Inc., a technology-enabled services company that is at the forefront of the movement to decentralize care for serious or complex illnesses. The addition of the BioIntelliSense medical grade BioButton® wearable devices and advanced analytics enables an enhanced level of data-driven care that, combined with clinical assessment, is designed to inform prioritization of care, allocation of resources and improved clinical workflow in treating and caring for patients with complex or high-risk conditions being cared for at home.

“Our strategic collaboration with Medically Home advances a shared vision for a scalable and patient-centric model of healthcare delivery,” said James Mault, MD, founder and CEO of BioIntelliSense. “High frequency vital sign trending data, combined with algorithmic-based alerting, provides clinicians with greater insights for patient care from in-hospital to home. This represents a significant advancement in admitting to home with confidence and bringing medical grade continuous monitoring to the lowest cost care setting.”

The rechargeable multi-parameter BioButton® wearable devices passively capture clinically validated vital signs of heart rate at rest, respiratory rate at rest and skin temperature, along with a broad range of physiologic biometrics, including activity levels, sleep tracking, body position and gait analysis. The BioCloud™ data analytics and algorithmic-based alerting enable actionable clinical triage and proactive clinical intervention through potential earlier detection of adverse trends.

The Medically Home model directly addresses the growing need for increased health system capacity and resiliency, while meeting the needs and preferences of patients, who often desire to be cared for in the comfort and convenience of their home. With the comprehensive Medically Home and BioIntelliSense solution, patients with conditions across a broad spectrum of severity, complexity, and risk can continue to be cared for safely at home with clinical accuracy, reducing the necessity for traditional building-centric care.

“BioIntelliSense provides a scalable medical-grade solution that allows for passive vital sign data collection from the home, dramatically reducing the cost and complexity of deploying traditional remote patient monitoring programs with improved patient experience,” said Pippa Shulman, DO, MPH, Chief Medical Officer, Medically Home. “As hospital capacity pressure mounts, this strategic collaboration further accelerates Medically Home’s platform reach and growing ecosystem of health systems and payers nationwide.”

BioIntelliSense (Booth #5025) and Medically Home (Booth #4641) will be exhibiting at HLTH November 13-16.

Visit AITechPark for cutting-edge Tech Trends around AI, ML, Cybersecurity, along with AITech News, and timely updates from industry professionals!

Related posts

Clinical AI Technology Leader Mendel Raises $18M in New Capital

Business Wire

BUDDI AI Launches End-to-End Revenue Cycle Automation Suite

PR Newswire

Ribon Therapeutics Secures $65 Million Financing

Business Wire